Hunan Huateng Pharmaceutical Co., Ltd. is preparing to exhibit at CPHI Milan 2026, welcoming laboratory researchers, biopharmaceutical developers, and industry partners at Stand 3H94 from October 6 to 8 at Fiera Milano.
As a key supplier for life sciences and drug discovery, Huateng Pharma will present its comprehensive portfolio of polyethylene glycol (PEG) derivatives engineered for bioconjugation, targeted drug delivery, and advanced research applications. The showcase will feature both polydispersed and monodispersed PEGs, alongside specialized linear, lipid, and multi-arm architectures.
Beyond catalog reagents, Huateng Pharma will emphasize its flexible CDMO capabilities, designed to support projects from early-stage laboratory development to large-scale production. Offering both GMP and non-GMP environments, the company’s technical services cover route design, analytical quality studies, process optimization, and regulatory validation.
Attendees visiting Stand 3H94 can also discover the company’s broader offerings in specialty chemical intermediates, cosmetic active ingredients, and research-grade veterinary APIs.
Sonia Lee, Head of Business Development, along with the technical team, will be on-site to discuss custom synthesis needs, collaborative R&D projects, and supply chain solutions with international laboratory and industry professionals.
Event Details
Event: CPHI Milan 2026
Dates: October 6–8, 2026
Venue: Fiera Milano, Milan, Italy
Booth: 3H94
About Hunan Huateng Pharmaceutical Co., Ltd.
Hunan Huateng Pharmaceutical Co., Ltd. specializes in the development and large-scale manufacturing of high-purity PEG derivatives, pharmaceutical intermediates, APIs, and specialty fine chemicals, supporting global advancements in pharmaceutical and biopharmaceutical R&D.
